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/or inhibit calcium uptake and potassium chloride plus
water loss. Further, by preventing cellular dehydration,

COMPOSITIONS AND METHOD OF TREATMENT
FOR SICKLE CELL ANEMIA

the drug would serve to preserve the deformability of
the sickle red blood cell, prevent sickling, and be an

extremely valuable therapeutic approach to the control

TECHNICAL FIELD
This invention relates to the compound phlorizin

benzylazide, pharmaceutical compositions thereof and

of sickle cell anemia crisis.
As a result, a large variety of structurally and mecha

their method of use for the treatment of sickle cell ane
mia.

posed for the treatment of sickle cell anemia. So far,

nistically dissimilar antisickling agents have been pro~
10 however, none of these have been found to be clinically

BACKGROUND ART
Sickle cell anemia results from a defect in the genetic

coding of the hemoglobin molecule. The abnormal he
moglobin S molecule in the red blood cells of sickle cell
anemia patients is relatively insoluble and prone to

deoxygenation-induced polymerization. When the

useful. Most inhibit red blood cell sickling either by
chemically modifying the hemoglobin S molecule to
prevent its aggregation or by increasing red blood cell
af?nity for oxygen. Approaches include the use of
acetylators, such as aspirin; cross-linking agents, such as

dimethyladipimidate; inhibitors of intra-molecular hy

sickle hemoglobin releases its oxygen at peripheral tis
sue sites, it undergoes aggregation which distorts the

drophobic bonds, such as urea; and chemical group
reactants, such as cyanate (as in U.S. Pat. No. 3,833,724
red cell’s normal biconcave disc appearance and the
to Cerami et al).
characteristic spiculated, “holly leaf’ or sickle shape is 20 Because of the critical role of hemoglobin S concen
formed. This aberrant cell distortion accounts for the
tration in the sickling process, it has been proposed that

clinical problems in this disease, namely hemolytic ane
mia and vascular stasis, occlusion and thrombosis.
The viscosity of the red blood cell interior is largely
a function of hemoglobin concentration. When cell
water content falls, the deformability of the red blood
cell decreases. This compromises the ability of the red
blood cell to maneuver through the microvasculature of

the body. This effect is magni?ed in the deoxygenated
sickle red blood cell because the rate at which the he

moglobin S polymerizes is greatly accelerated by cellu
lar dehydration, because aggregation is extremely de
pendent upon the deoxy-hemoglobin S concentration.
There is also evidence that the sickle cell becomes de

hydrated during deoxygenation and this initiates the
cell sickling.
Additional research has indicated that a dysfunc
tional membrane of the sickle red blood cell plays a

fundamental roll in disease pathophysiology. Studies
indicate that the deformation or sickling process result

ing from deoxygenation requires about l0—l5 seconds
to complete. Thus, it may be necessary for the blood in
the microvasculature to slow abnormally before sick
ling of most cells occurs. This slowing could be induced
because of abnormal interactions between the sickle cell 45
and the micro-blood vessel wall clue to an altered red

blood cell membrane construction. There may also exist

subpopulations of abnormally dense and in?exible red
blood cells re?ecting cellular dehydration and in
creased internal viscosity.
These features are presumed to be due to altered ion

flux and homeostasis controlled by the cell membrane.
Furthermore, when a cell sickles and unsickles repeat
edly, the membrane is affected and the cell becomes

even a modest reduction of mean cell hemoglobin con

centration in the sickle cell will greatly decrease any
propensity to sickle. Clinical trials in which sickle pa
tients on a low sodium diet were given anti-diuretic

hormone to reduce plasma Na+~osmolality in hopes of
producing a secondary reduction in cell hemoglobin S
concentration had very limited success. Low plasma
Na+ levels simply could not be maintained. Further,
this is an ineffective means of increasing red blood cell
water content. Other investigators have used the antibi
otic Monensin to induce a Na+-selective leak in the red
blood cell membrane. It was found that this Na+-iono

phore produced an influx of sodium salt and water into
the sickle cell. This increased hydration produced some
improvemement in the deformability of the red blood

cell. Disadvantageously, however, Monensin is highly
toxic in experimental animals at micromolar levels.
From the above, it is clear that a need exists for a safe,

effective and clinically useful compound for the treat
ment of sickle cell anemia. During the course of experi
ments designed to photoaf?nity label and identify the
glucose transport carrier in normal human red blood
cells, we- found that phlorizin benzylazide caused he
molysis of the red blood cells under certain conditions.
The phlorizin derivative has a high, but reversible, af
?nity for the sugar transporter in subdued light and is a
potent inhibitor of the transfer mechanism. After allow
ing the compound to associate with its speci?c mem
brane receptor, activation with light was expected to
result in relatively speci?c, covalent, irreversible label
ing of the transporter. However, in our initial experi
ments, even before illumination, the red blood cells

irreversibly sickled, remaining deformed even when the 55 were found to swell and, in a time and drug dose
dependent manner, burst even in an isotonic buffer.
hemoglobin S is reoxygenated in the lungs. These irre
These results suggested to us that this compound has
versibly sickled cells (hereinafter ISC) have a drasti
potential usefulness as a membrane perturbant and anti
cally reduced water content and, thus, high hemoglobin

sickling agent. Further experiments were then con
sium content. They may also be ATP-depleted. ISC’s 60 ducted to demonstrate the safety and effectiveness of
phlorizin benzylazide for use in a method of treating
have short intravascular life-spans and the severity of
sickle cell anemia.
the hemolytic process is directly related to the number
of these cells in a patient’s circulation. Presumably, the
SUMMARY OF THE INVENTION
permanently deformed cytoskeletons of the ISC’s make
It is, accordingly, one object of the present invention
65
them unable to negotiate through capillaries.
to provide pharmaceutical compositions, including
Based on the above evidence, researchers have
phlorizin benzylazide as an active ingredient, for the
sought a drug that would interact with the red blood
effective and safe treatment of sickle cell anemia.
cell membrane and increase sodium permeability and

concentrations, as well as high calcium and low potas

4,665,058
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A further object of the present invention is to provide

4

impermeant to this scam and, therefore, provides an

a safe and effective method of use of phlorizin benzyla

osmotic force for water as well as salt to enter the red

zide containing compositions in treating sickle cell ane

blood cell. This ?ux of water and salt serves to swell the
red blood cell to a spheroid shape and reduce the con

mla.

Other objects and advantages of the present invention

centration of hemoglobin S in the cell below a critical

will become apparent as the description thereof pro
ceeds.

cantly delaying sickling until the hemoglobin S can

In satisfaction of the foregoing objects and advan
tages, there is provided by this invention anti-sickling

again become oxygenated.

compositions comprising as the active ingredient an

the present invention include an effective amount of the

effective amount of the compound phlorizin benzyla
zide. Also provided are methods for administration of
the anti-sickling compositions of this invention to pa
tients suffering from sickle cell anemia and from the

active ingredient phlorizin benzlyazide admixed with a

crisis episode of the disease. Preferably, the anti-sickling

excipients include water, peanut oil, olive oil or syrup.
Of course, other known medicinal excipients may be
used.

composition is administered in an intravenous load dos

age of between 0.5-l.0 milligrams of the phlorizin ben

zylazide active ingredient per kilogram of the patient.
Since the active ingredient has an unusually long

concentration, thereby preventing sickling or signifi
The pharmaceutical preparations or compositions of

pharmaceutical organic or inorganic excipient. Suitable
excipients are substances that do not react with the

novel inhibitory compounds. Speci?c examples of such

Preferably, the compositions are designed and

adapted to be administered parenterally such as by sub
biological half-life of approximately 75 hours, mainte 20 cutaneous depo injection or I.V. drip. Advantageously,
nance dosages of from 0.05 to 0.2 milligrams of phlori
this avoids the risks involved in oral administration
zin benzylazide per kilogram of patient weight are then
wherein the phlorizin portion of the molecule could be

administered to the patient daily. This procedure advan

tageously serves to maintain an approximately 6—l2.5

jtM concentration of phlorizin benzylazide (unbound)
in the bloodstream of the patient. Phlorizin benzylazide

hydrolyzed by the intestinal epithelia to phloretin. As is
well known, phloretin readily enters the blood stream
and causes at appropriate levels toxic effects at all sites

in the body.

at these concentration levels interacts with the red
As more fully shown in the examples discussed be
blood cell membrane, allowing salt and water to enter
low, an effective amount of the active ingredient is
the cell under the osmotic drive of the impermeant
approximately a 6 to 12.5 uM blood level concentration
hemoglobin. The additional salt and water swell the red 30 of phlorizin benzylazide. At this concentration level
blood cells to a spheroid shape and reduce the concen
there is little or no cell lysis due to the incoming ?ux of
tration of hemoglobin S below a critical concentration
so that upon deoxygenation, sickling does not occur.

Additionally, doses of phlorizin benzylazide effective to
prevent sickling at this concentration cause few or no

sickle cells to burst. Further, at potentially therapeutic
doses, phlorizin benzylazide is not grossly toxic and,
therefore, provides a relatively safe method for treating
sickle cell anemia.

water and salt across the cell membrane. It, however,

should be recognized that higher concentration levels

of phlorizin benzylazide could be used, for example, in
an emergency to combat a sickle cell crisis. The higher
concentrations are anticipated to be followed by a trans

fusion of whole blood to replace those red blood cells in

the patient that burst under the in?uence of the phlori
zin benzylazide and to bring the phlorizin benzylazide

BRIEF DESCRIPTION OF THE DRAWINGS

concentration level in the blood back down to a safer

FIG. 1 graphically demonstrates the kinetics of

concentration range.

Thus, it should be appreciated that the method of
treating
sickle cell anemia includes the step of adminis
FIG. 2 graphically shows that phlorizin benzylazide
causes an increase in intracellular volume of red blood 45 tering parenterally a load dosage of from 0.5-1.0 milli
grams of phlorizin benzylazide per kilogram of patient
cells.
weight. This, of course, may be done over a period of
FIG. 3 shows that red blood cell swelling and lysis
time intravenously or by one or more subcutaneous
are dependent upon the concentration of phlorizin ben

phlorizin benzylazide-induced hemolysis.

zylazide present.

_

FIG. 4 demonstrates how phlorizin benzylazide in
hibits red blood cell sickling induced by deoxygenation.
FIG. 5 graphically depicts the absorption and elimi
nation rate of phlorizin benzylazide in rats.

depo injections.

The higher end of the range is appropriate when
seeking to combat the effects of sickle cell crisis with
dosage levels above the range providing increased risk
of side effects from red blood cell lysis. The lower end

and middle portion of the load dosage range is appropri

DETAILED DESCRIPTION OF THE
55 ate when using phlorizin benzylazide as a prophylaxis
INVENTION
with load dosages less than the range failing to provide
satisfactory therapeutic or anti-sickling action. For ex
As indicated above, the present invention is drawn to
ample, a load dosage level of approximately 0.75 mg per
novel pharmaceutical compositions containing an effec

tive amount of phlorizin benzylazide as the active ingre

kilogram of patient weight provides the patient with a

dient. The compositions are useful in the method of the 60 blood concentration level of phlorizin benzylazide ther

present invention for treating sickle cell anemia.
It is believed the structural features of phlorizin ben
zylazide allow it to interact with a component of the red

blood cell membrane, possibly the glucose transporter.
The phlorizin benzylazide distorts the glucose trans

apeutically effective in resisting hemolytic anemia and

vascular stasis, occlusion and thrombosis associated
with sickle cell anemia. Further, such load dosages
bring the blood level concentration of phlorizin ben

zylazide in the patient to approximately the 6—l2.5 uM

porter or some other integral protein to form a micro
pore or seam between the membrane proteins ‘and the

level, on the .basis that the agent distributes solely in the
extracellular fluid and is not sequestered in various

lipid-bilayer of the membrane. Hemoglobin remains

body compartments. Advantageously, at this level, cell

5
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phlorizin. Rfvalue of the presumed compound GNC in

swelling and anti-sickling action are maximized with
little or no red blood cell lysis occuring.
An additional advantage of the composition of the

25% MCOH/CHC13 was 0.25.

Compound GNC (0.96 g in 100 ml methanol) was
catalytically hydrogenated with 150 mg 10% Pd on
charcoal for 1 hr at 22° C. at atmospheric pressure, and

present invention is the unusually long biological half
life enjoyed by the phlorizin benzylazide. The half-life
has been shown experimentally to be of approximately
75 hours. Thus, after the load dosage is administered,
initial anti-sickling action is long lived and maintenance
dosage to maintain the blood cell concentration level at
approximately the 6—12.5 uM level is quite small. In

then 3 hr. at 55° C. at 30 cm H2O pressure. At lower

particular, 0.05 to 0.2 milligrams of phlorizin benzyla
zide per kilogram of patient weight are required per day

was dissolved in 8 ml methanol and mixed with 10 ml
Sephadex G-10 slurry equilibrated in 50% methanol. ‘

temperatures reduction was incomplete and yielded an
unstable orange product. The catalyst was removed and
the methanol was evaporated in vacuo to yield crude

phlorizin-5’-benzylamine (0.84 g, 92%). The product

Finally 8 ml H2O was added and the resulting slurry
to continue to provide effective anti-sickling action to
was added to the top of a Sephadex G-lO column (2.5 X
the patient. Again, it should be recognized that the
higher end of the range is for combatting the effects of 15 27 cm) likewise equilibrated in 50% methanol. Elution
sickle cell crisis and the lower end and middle portion is
for less severe periods of the affliction. For example,
normally a maintenance dosage of approximately 0.125

was conducted with 0.8 L 50% methanol followed by
0.7 L 55% methanol and 1.0 L 60% methanol. The
amine was eluted in the 1.1-2.0 L fraction. If the amine

mg of phlorizin benzylazide per kilogram of patient

had been contaminated prior to this chromatography,
phlorizin was readily separated at this step and could be
recovered in the 0.36-0.66 L fraction. Phlorizin-5'-ben
zylamine was obtained by evaporating the solvent and
crystallization from aqueous methanol as the monohy
drate (0.55 g, 60%); after drying at 80° C. in vacuo its

weight provides effective therapeutic action.
The following synthesis and examples are presented
to further illustrate the invention, but it is not to be
considered as limited thereto. In the examples, the for

mation of synthetic intermediates was monitored by 25
m.p. was l97°—200° C.
thin layer chromatography performed on Silica Gel 60
F-254 plates using the solvent systems indicated. The
structure of the isolated compounds was established

Elemental Analysis:

spectrophotometrically. Proton-NMR spectra (100
MHz) were recorded on a Varian HA-100 Spectrome 30

ter using (CH3)4Si (=0.00) as internal standard and
acetone-d6, acetic acid or trichlorosilene as solvents.

C

H

Calculated for C28H31010N.H201

60.10

5.94

2.54 /

N

Found for the reaction product:

60.30

5.90

2.51

Chemical shifts are given in ppm. Infra-red spectra
In order to verify that the reaction conditions were
were taken in KBr pellets on a Beckman IR-8 spectrom
eter and ultraviolet spectra on an Aminco DW-2a 35 sufficient to reduce the secondary hydroxyl group of

GNC, the phlorizin-5’-benzylamine reaction product

UV/VIS spectrophotometer.

was quantitatively acetylated with acetic anhydride in
the presence of pyridine. Theoretical incorporation is 8

Elemental and functional group analyses were per

formed by Galbraith Laboratories, Knoxville, TN and
by the Laboratorium ?ir Organische Chemie, Eiden

genossische Technische Hochschule-Zentrum, Ziirich,

40

moles acetate/mole glycoside. Found for phlorizin-5'
benzylamine: 7.82 moles acetate/mole phlorizin-5’-ben

Switzerland.

zylamine (97.8%).

Melting points were taken on a Thomas Hoover cap
illary melting point apparatus and are uncorrected. ,

An acetamide derivative of the reaction product pre
pared by coupling acetic acid and the amine in methanol

Synthesis of Phlorizin Benzylazide

with EDAC, was crystallized from 30% methanol as
45 the monohydrate. After drying at 80° C. in vacuo its

Phlorizin (7 mmol) and p-nitrobenzaldehyde (5
mmol) were dissolved in 84 ml methanol and cooled to
0° C. Under a nitrogen atmosphere, 14 meq of 1N KOH

were added dropwise with magnetic stirring and the
reaction was allowed to incubate for 2 hrs. at 0° C. and 50
then 1.5 hrs. at 50° C. The reaction mixture was re

cooled to 0° C. and neutralized by the dropwise addi
tion of 14 meq of 0.5N HCl. The solvent was removed

m.p. was: 215° C. after softening at 149° C.
Elemental Analysis:

~ Calculated for C30H33O1 1N:
Found for acetamide derivative

..

C

H

N

61.64
61.58

5.69
5.90

2.49
2.32

of the reaction product:

in vacuo to yield a brown syrup containing primarily
the presumed carbinol (carbinol was not sufficiently 55 Further evidence con?rming the compound to be
phlorizin-5'-benzylamine was provided by comparing
stable to be analyzed) and unreacted phlorizin. The
its proton NMR spectra with that of phlorizin. The
mixture was dissolved in 10 ml CHCl3/CH3OH (4:1)
A2B2'pattern at 2.88 and 3.50 ppm arising from the
and subjected to flash chromatography on a column of
—CH2CH2CO- moiety in phlorizin also appears at
Silica Gel 60 (4.5><26 cm) that had been pressure
packed with chloroform. Elution was conducted with 60 2.87 and 3.49 ppm in the spectra of phlorizin-5’-benzyla
mine (in both compounds the triplet at 3.5 ppm is par
0.75 L 15% methanol in chloroform, followed by 0.5 L
tially obscured by the signals arising from the protons in
18% and then 0.5 L 22% of the same solvent mixture.
the glucose moiety). The B-ring AA’BB'-system at 6.72
Thin layer chromatography was used to monitor the
and 7.10 ppm remained unchanged, but phlorizin’s A
fractionation: the’ eluate volume between 0.4-0.5 L
contained essentially pure 2'-O-(B-D-gluco-pyranosyl) 65 ring AB-system at 5.99 and 6.25 ppm was converted to
a 1H singlet at 7.42 ppm in compound phlorizin-5’-ben
5'-p-nitrobenzy1 carbinol (hereinafter called GNC) (0.8
zylamine. The new C ring AA'BB’ system in compound
g', 20%) while the 0.5-1.4 L eluate contained 2.4 g of a
phlorizin-S-benzylamine gave signals at 6.54 and 6.98
mixture of GNC contaminated with approximately 20%

7
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ppm and the new —CH2 group is seen as a 2H singlet at

and volume of cells passing through an analysis cham

3.72 ppm.

ber, was used to make these measurements.

Since phlorizin benzylazide was expected to be
photolabile, it was synthesized and isolated in subdued
light. Cold 0.5N HCl (1.4 meq) was added slowly with
magnetic stirring to 0.14 mmol of the phlorizin-5’-ben
zylamine in 8 ml acetone (—2° C.) followed by drop
wise addition of 0.28 mmol NaNOg in 0.5 ml H2O. The

The dose-response curve of phlorizin benzylazide
acting as a hemolytic agent of normal cells is shown in
5

FIG. 3 and the following table:
Phlorizin Benzylazide, K M

% Hemolysis

t;

62
Si
16

66 i 8
41 i 9.6
31 i 8.6

233
260
450

8

O

—

4

o

_

reaction mixture was stirred for 5 min and then l.4

mmol NaN3 (in 1 ml H2O) was added. After 10 minutes
excess urea was added with stirring. Acetone was then

removed in vacuo and the product azide was precipi

tated from the reaction mixture by slow addition of ice
cold H2O. The isolated material was recrystallized from

In FIG. 3, potency is expressed as the ratio, % hemoly
sis/t5, where t; represents the time (seconds) required to
achieve 50% of the total hemolysis produced by the
particular concentration of the compound within the

15 ml 30% aqueous methanol to yield small white crys

tals as the monhydrate (0.053 g, 60%) with the follow
ing m.p.: softens at 115° C., discolors 205° C., decom

poses >250° C. R/=0.44 in chloroform/methanol, 7:3.
The infra-red spectra possessed the sharp 2120 cm-1
and 1280 cm~1 absorption peaks characteristic of an
azide group. It has two major UV absorption maxima in

time of our measurements (700 sec). The cells used for
these experiments were 2 hours old, and subjected to an
incubation for 30 minutes before the addition of phlori

ethanol or water; one at 255 nm attributable to the azide
group, and the second at 280 nm which shifts to 334 nm

zin benzylazide and continuing thereafter at approxi
mately 4° C. (n=4). Advantageously, cell swelling oc

in 0.05M sodium borate, pH 9.3 (334=2.95>< 104 cm-1

M-l, 255=2.35>< 104 cm'-1M-1.

20

25 curred at low phlorizin benzylazide levels and no cell

lysis was observed at concentrations below 10 uM.

Thus, this blood level concentration provides anti-sick
ling action by reducing the concentration of hemoglo

EXAMPLE 1
Human red blood cells were obtained by venepunc

bin S with an in?ux of water and/or salt into the cells.
Further, this is accomplished with little or no red blood

ture into Na citrate or EDTA vacutainers. They were

used directly or stored in serum at 4° C. for various

cell lysis and, therefore, minimum adverse side effects.

times. Serum and leucocytes were removed by siphon

EXAMPLE 2

ing and the settled red blood cells were washed once

and ?nally made to a 0.15% suspension with isotonic

NaCl containing 5 mM KH2PO4 (pH 6.2). These cells

This example demonstrates that phlorizin benzylazide
35

were kept at 2° C. for selected periods of time during a

inhibits sickling induced by deoxygenation in vitro.
Whole blood was obtained from several volunteer
sickle cell disease patients and was stored for several

?rst incubation. From this point on, all experiments
were performed in subdued light to protect the light

days at 4° C. However, for these experiments, the cells
did not experience a cold incubation. Instead, whole
blood was diluted into pre-warmed (37° C.) isotonic

sensitive phlorizin benzylazide. The phlorizin benzyla
zide obtained from the synthesis described above was
added at the desired concentrations, and during this
variable temperature second incubation (2°-4° C. in

phosphate-buffered saline (1 phlorizin benzylazide,

presence of phlorizin benzylazide), the turbidity of the

12.5 uM) which was then deoxygenated by continuous

cell suspension was monitored at 610 nm with a continu

passage of an 100% Argon stream (1 liter/min) over a

ously recording spectrophotometer to measure hemoly

45

sis. A relatively constant level of absorbance of light
indicates decreased hemolysis occurring at the lower
dosage and this was veri?ed by concomitant counting

rotating thin ?lm of the suspended cells. Aliquots were
periodically taken, without 02 exposure, and ?xed in
1% glutaraldehyde. These samples were then examined

under phase microscopy for the degree of sickling by

of cells with a hemacytometer. Some typical data are

counting ?elds of at least 100 cells using a single blind,

shown in FIG. 1 showing the change in absorbance of
light (note axis A) when the drug was added (at zero

experimental protocol.

time). The higher level of Phlorizin Benzylazide caused
not only a greater percentage of cell lysis (an absor

phlorizin benzylazide present, about 35-40% of the
cells from these patients assumed the typical sickle
shape (only cells having a 3:1, lengthzwidth ratio were

The data shown in FIG. 4 illustrate that without

bance of 0.087 represents 100% lysis) but the rate at
which the cells burst was much faster.

Evidence that lysis is preceded by a progressive

55

considered to be sickled); whereas, with the phlorizin
benzylazide, the deoxygenation caused a maximum

swelling of the red cell is shown in FIG. 2. In these
increase of 5% more than the 10% of cells already
experiments (n=2) red cells had been stored in serum
sickled at zero time. Actually, the effect of phlorizin
for 30 hours, and experienced a ?rst incubation for 60
min at 4° C. and a second incubation with 12.5 )uM 60 benzylazide is even more dramatic. In the absence of
phlorizin benzylazide, bizarre shape changes occurred
phlorizin benzylazide at 4° C. for 5 and 10 min. The
in almost 100% of the cells when 02 tension was low
integrated curves show that untreated red cells, with or
without a 10 min incubation #2, have a mean volume of

ered; whereas, with the phlorizin benzylazide, a uni

form spherocytosis was induced in most cells. The
pendent increase in mean cell volume occurs with es 65 l0-l5% sickled cells present at zero time are probably

about 80 p3. When the compound is added, a time de

sentially no lysis within this time span (area under the
curve remained unchanged). The Coulter Counter, an
automated instrument which determines the number

the so-called irreversibly sickled cells (ISC). It should
be emphasized that no signi?cant hemolysis occurred in

Example 2.
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will become apparent to those skilled in the art, the

EXAMPLE 3
An animal study was then conducted to determine

invention is not to be considered as limited thereto.

We claim:
1. A pharmaceutical composition for use in the treat
ment of sickle cell anemia patients comprising as an
active ingredient an effective amount of phlorizin ben

the absorption and elimination and characteristics of the

phlorizin benzylazide and the resulting level of safety.
Three adult rats of approximately 450 grams each were
injected intraperitoneally at zero time in l, 2 and 3 mg

zylazide.

doses of tritiated phlorizin benzylazide (875,000

2. The composition set forth in claim 1, including a
pharmaceutical excipient so as to be adapted for admin

cpm/mg). Thereafter, serial tail blood samples were
taken at varying times and analyzed for tritium. Maxi
mal absorption of the-compound from the peritoneal
compartment was slow (note FIG. 5) and maximum

istration parenterally.
3. The composition set forth in claim 1, in load dosage
form including from 0.5-1.0 mg of active ingredient per

blood level concentrations were obtained only after
about 20 hours. The initial very rapid entry and elimina
tion of a small fraction of the radioactivity was probably

kilogram of the patient.
4. The composition set forth in claim 3, wherein said

tritiated H20 and other radioactive impurities. Peak

load dosageis approximately 0.75 mg of active ingredi
ent per kilogram of the patient.

concentrations of the agent in the blood were reached at
identical times in the three animals and were 2.5, 5.1 and

5. The composition set forth in claim 1, in mainte
nance dosage form including from 0.05 to 0.2 mg of

6.3 pM, roughly proportional to the dose administered.

active ingredient per kilogram of the patient per day.

The absorption rate constant was estimated to be 0.07
hr'-1. Elimination of the drug was a ?rst order process
and the mean half life was an unusually long 75 hours as

6. The composition set forth in claim 5, wherein said
maintenance dosage is approximately 0.125 mg of active

ingredient per kilogram of the patient per day.

described above. This feature could, of course, offer
7. The composition set forth in claim 1, wherein said
advantages for therapy in a sickle cell crisis wherein
effective amount of said active ingredient is approxi
long term effectiveness is desired. The animal receiving 25 mately a 6—12.5 PM concentration of phlorizin benzyla
the lowest dosage was sacri?ced after 5 days while the
zide in the blood of the patient.
other two were observed for a period of 7 weeks. None
8. A method for the treatment of sickle cell anemia in
of the animals exhibited any unusual behavioral abnor
a patient comprising administering to the patient an
malities. Gross examination of all tissues were un

effective dosage amount of phlorizin benzylazide.

remarkable and histological examination of the liver

9. The method of claim 8 wherein said effective dos

and kidney from the two older animals showed no pa

age amount of phlorizin benzylazide is administered
parenterally in a pharmaceutical excipient as a composi

thology.
In summary, numerous benefits have been described

tion.

which result from employing the concepts of the pres

10. The method of claim 8, including the step of ad
ministering a load dosage to the patient of from 0.5-1.0

ent invention. A novel pharmaceutical composition
including an effective amount of the active ingredient

mg of phlorizin benzylazide per kilogram of the patient.

phlorizin benzylazide is disclosed. The compositions are

11. The method of claim 10, wherein said load dosage
useful in a method for treating sickle cell anemia. Ad
is
approximately
0.75 mg of phlorizin benzylazide per
vantageously, the compositions serve to lower the he
moglobin S concentrations in the red blood cells of 40 kilogram of the patient.
12. The method of claim 8, including the step of ad
sickle cell anemia victims and, thereby, prevent sick
ministering a maintenance dosage to the patient of from
ling. As a further advantage, the biological half-life of
0.05 to 0.2 mg of phlorizin benzylazide per kilogram of
the phlorizin benzylazide is approximately 75 hours.

Therefore, the compositions provide a patient, particu
larly when undergoing sickle cell anemia'crisis, with

the patient per day.
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safe and effective long term anti-sickling action. Fur
ther, only minor maintenance dosages of the phlorizin ’
benzylazide are required to maintain the anti-sickling
action over a still longer period.
The invention has been described herein with refer
ence to a certain preferred pharmaceutical composition

13. The method of claim 12, wherein said mainte
nance dosage is approximately 0.125 mg of phlorizin

benzylazide per kilogram of the patient per day.
14. The method of claim 8, including the step of main
taining a phlorizin benzylazide concentration of approx
imately 6—l2.5 uM in the blood of the patient to inhibit

cell sickling.
t

embodiment. However, as obvious variations thereon
55
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